- Home
- RSF vs KZIA Comparison
RSF vs KZIA Comparison
Compare RSF & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RSF | KZIA |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.1M | 74.4M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | RSF | KZIA |
|---|---|---|
| Price | $14.64 | $6.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 11.8K | ★ 250.2K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.81 | $2.86 |
| 52 Week High | $16.23 | $17.40 |
Technical Indicators
Market Signals| Indicator | RSF | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 63.59 | 40.43 |
| Support Level | $14.31 | $5.30 |
| Resistance Level | $14.47 | $7.08 |
| Average True Range (ATR) | 0.09 | 1.07 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 86.71 | 22.34 |
Price Performance
Historical ComparisonAbout RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.